Eli Lilly and Co. has extended a research agreement with Jubilant Organosys Ltd., a Bangalore, India-based drug firm, the
companies announced Tuesday morning.
Jubilant and Indianapolis-based Lilly extended the collaboration, which began
in 2005, by five years.
Under the pact, Jubilant will receive research funding and payments for reaching drug-discovery
and development milestones. Lilly will own any compounds developed by the partnership and will be responsible for marketing
them.
The partnership has already delivered multiple discovery milestones and preclinical
drug candidates, the companies said.
Lilly and Jubilant also have a joint venture for early-stage drug development,
Vanthys Pharmaceuticals, that was established in 2008.
Please enable JavaScript to view this content.